Immunological aspects of mesenchymal stem cell therapy for ALS
Neuroinflammation contributes to ALS progression, yet effective immune-modulating therapies remain limited. Despite the enthusiasm regarding stem cell therapy as a means of regeneration, it is interesting that the first FDA approval for mesenchymal stem cells (MSC) was for immune modulation, graft versus host disease (GVHD), not rejuvenation. We focus here on the immunological mechanisms through which MSC, particularly via induction of regulatory T cells, may slow…